| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH |
From the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, and the Department of Biostatistics, Holden Comprehensive Cancer Center, the University of Iowa Hospitals and Clinics, Iowa City, Iowa.
Address reprint requests to: Anil K. Sood, MD, University of Iowa Hospitals and Clinics, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, 200 Hawkins Drive, Iowa City, IA 52242; E-mail: anil-sood{at}uiowa.edu.
OBJECTIVE: To estimate the association of preoperative CA 125 levels with outcome in primary ovarian cancer patients.
METHODS: One hundred forty-two patients with epithelial ovarian cancer, who had a serum CA 125 level drawn before surgery, were retrospectively evaluated. The relationship of preoperative CA 125 levels and various preoperative and postoperative variables was evaluated. CA 125 levels were determined using a solid-phase immunoassay.
RESULTS: The median CA 125 value for all patients was 582 U/mL (range 7–52,930 U/mL). Preoperative CA 125 values did not correlate with increasing age (P = .40), but were found to be significantly associated with serous histology compared with other histology (median CA 125 of 870 versus 334 U/mL, P = .02), high-stage (III/IV) compared with low-stage (median CA 125 of 893 versus 174 U/mL, P < .001), high tumor grade (3) compared with grade 1 or 2 (median CA 125 of 928 versus 323 U/mL, P < .001), and the presence of ascites compared with absence of ascites (median CA 125 of 893 versus 220 U/mL, P < .001). Suboptimal cytoreduction (more than 1 cm residual) was associated with significantly higher CA 125 levels (1067 U/mL) compared with individuals with optimal cytoreduction (399 U/mL, P < .001). Preoperative CA 125 values less than 500 U/mL had a positive predictive value for optimal cytoreduction of 82%, but a poor negative predictive value of 48%. After adjusting for covariates, there was a significant association between CA 125 levels and disease-specific survival. As preoperative CA 125 levels increased, the risk of death increased except at the highest values of CA 125.
CONCLUSION: Preoperative CA 125 is an independent risk factor for death due to disease in ovarian cancer, but not a reliable predictor of optimal cytoreduction.
This article has been cited by other articles:
|
|
 |
|
  B. Van Calster, D. Timmerman, T. Bourne, A. C. Testa, C. Van Holsbeke, E. Domali, D. Jurkovic, P. Neven, S. Van Huffel, and L. Valentin Discrimination Between Benign and Malignant Adnexal Masses by Specialist Ultrasound Examination Versus Serum CA-125 J Natl Cancer Inst, November 21, 2007; 99(22): 1706 - 1714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Timmerman, B. Van Calster, D. Jurkovic, L. Valentin, A. C. Testa, J.-P. Bernard, C. Van Holsbeke, S. Van Huffel, I. Vergote, and T. Bourne Inclusion of CA-125 Does Not Improve Mathematical Models Developed to Distinguish Between Benign and Malignant Adnexal Tumors J. Clin. Oncol., September 20, 2007; 25(27): 4194 - 4200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Fader and P. G. Rose Role of Surgery in Ovarian Carcinoma J. Clin. Oncol., July 10, 2007; 25(20): 2873 - 2883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Axtell, M. H. Lee, R. E. Bristow, S. C. Dowdy, W. A. Cliby, S. Raman, J. P. Weaver, M. Gabbay, M. Ngo, S. Lentz, et al. Multi-Institutional Reciprocal Validation Study of Computed Tomography Predictors of Suboptimal Primary Cytoreduction in Patients With Advanced Ovarian Cancer J. Clin. Oncol., February 1, 2007; 25(4): 384 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Y. Han, C. N. Landen Jr, A. A. Kamat, A. Lopez, D. P. Bender, P. Mueller, R. Schmandt, D. M. Gershenson, and A. K. Sood Preoperative Serum Tissue Factor Levels Are an Independent Prognostic Factor in Patients With Ovarian Carcinoma J. Clin. Oncol., February 10, 2006; 24(5): 755 - 761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-i. Akahira, Y. Sugihashi, T. Suzuki, K. Ito, H. Niikura, T. Moriya, M. Nitta, H. Okamura, S. Inoue, H. Sasano, et al. Decreased Expression of 14-3-3{sigma} Is Associated with Advanced Disease in Human Epithelial Ovarian Cancer: Its Correlation with Aberrant DNA Methylation Clin. Cancer Res., April 15, 2004; 10(8): 2687 - 2693. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Mandelin, H. Lassus, M. Seppala, A. Leminen, J.-A. Gustafsson, G. Cheng, R. Butzow, and R. Koistinen Glycodelin in Ovarian Serous Carcinoma: Association with Differentiation and Survival Cancer Res., October 1, 2003; 63(19): 6258 - 6264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. Cooper, J. M. Ritchie, C. L. W. Broghammer, J. Coffin, J. I. Sorosky, R. E. Buller, M. J. C. Hendrix, and A. K. Sood Preoperative Serum Vascular Endothelial Growth Factor Levels: Significance in Ovarian Cancer Clin. Cancer Res., October 1, 2002; 8(10): 3193 - 3197. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
